Open AccessEffect of GLP-1 Mimetics on Blood Pressure and Relationship to Weight Loss and Glycemia Lowering: Results of a Systematic Meta-Analysis and Meta-Regression
Author(s) -
M. Katout,
Hong Zhu,
Jessica Rutsky,
P. Shah,
Robert D. Brook,
Jixin Zhong,
Sanjay Rajagopalan
Publication year - 2013
Publication title -
american journal of hypertension
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.009
H-Index - 136
eISSN - 1941-7225
pISSN - 0895-7061
DOI - 10.1093/ajh/hpt196
Subject(s) - medicine , liraglutide , exenatide , glycemic , weight loss , meta analysis , blood pressure , placebo , confidence interval , lixisenatide , type 2 diabetes , diabetes mellitus , semaglutide , cardiology , endocrinology , obesity , insulin , alternative medicine , pathology
Incretin therapies such as glucagon-like peptide 1 (GLP-1) agonists are commonly used for the treatment of type 2 diabetes mellitus. GLP-1 mimetics, besides improving glycemic control, have been shown to influence multiple pathways regulating blood pressure (BP). We investigated the GLP-1 analogs effects on BP from published randomized studies using a meta-analytic approach.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom